DEXA is the global gold standard for assessing muscle mass, its distribution, body fat, and bone density. It detects asymmetries in muscle development, allowing for tailored nutritional and training programs that maximize performance. It also provides a clear roadmap for monitoring recovery after injury.

In cases of weight reduction through pharmacological treatments such as Mounjaro or Ozempic, DEXA ensures that fat—rather than muscle mass—is primarily reduced. This enhances the safety and reliability of therapy, verifying its true effectiveness while protecting patients from potential deficiencies.

In weight-management programs, DEXA serves as the most accurate tool (gold standard) to determine whether weight loss results from fat reduction, muscle loss, or changes in water balance. This ensures that progress is not assessed merely through the scale or conventional bioimpedance devices but through advanced, accurate data that confirm true health improvements.

Many conditions are strongly linked to visceral fat accumulation, muscle mass reduction, and low bone density—factors often overlooked in standard assessments. DEXA detects these markers with precision, enabling early prevention of diseases such as type 2 diabetes, hypertension, and cardiovascular disorders.

For women in menopause, DEXA offers a comprehensive picture of both bone density loss and fat redistribution. This enables early prevention of osteoporosis and cardiometabolic diseases while allowing for better nutritional and exercise adjustments.

Longevity and preventive health require continuous monitoring. DEXA provides a “health map” that tracks lean muscle mass (LMI and ALMI scores), bone density, and visceral fat levels—all key determinants of quality of life and vitality in older age.